NeuroSense Therapeutics Ltd. - NRSN Price-to-Projected Revenue Ratio
NeuroSense Therapeutics (NRSN) is a biopharmaceutical innovator developing comprehensive therapies for neurodegenerative pathologies via RNA regulation. The forward P/S valuation ratio clearly demonstrates the dynamics of market expectations, where determines the current level of this parameter. Potential revenue is based on the treatment of Parkinson's disease and ALS, however, a high burn rate and dependence on clinical trials create significant financial risks.
Analytical breakdowns for neurosense-tx.com (NRSN)
- market price and analyst price targets:
- issuer market value details:
- book value of equity indicators:
- company liabilities and liquidity data:
Total Debt to Equity Ratio NeuroSense Therapeutics|NRSN - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital NeuroSense Therapeutics Ltd.|NRSN - Aggregate Debt Obligations|Debts to Book Capitalization NeuroSense Therapeutics|NRSN - Long-Term Debt|Company Short-Term Debt NeuroSense Therapeutics|Quick Ratio neurosense-tx.com
- financial results and valuation multiples details:
NRSN - Net Profit|Expected Profit NeuroSense Therapeutics|NRSN - Market Cap to Net Income|Forward P/E Multiple NeuroSense Therapeutics Ltd.|NRSN - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio NeuroSense Therapeutics|NRSN - Operating profit EBITDA|Net earnings per share for the last 12 months NeuroSense Therapeutics|NRSN - Earnings per share for the last four quarters|Quarterly EPS earnings growth neurosense-tx.com|NRSN - Expected net earnings per share growth this year|Earnings growth forecast for next year NeuroSense Therapeutics
- revenue and sales details:
Summary company analysis:NeuroSense Therapeutics, Ltd. NRSN
Forward P/S measures market capitalization relative to projected revenue, allowing an investor to determine the degree of an asset's overvaluation and assess the potential for correction should expectations shift. By analyzing the estimated forward P/S, one can filter out speculative noise, which is critical for NeuroSense Therapeutics (NRSN), as its current valuation is based not on present earnings, but on the high-risk results of clinical trials for ALS drugs.
Competitor analysis
Price-to-Projected Revenue Ratio Biogen BIIB|NBIX: Market Cap to Projected Revenue|RGC - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Axsome Corp AXSM|ACAD: Forward P/S Multiple|Market Cap to Future Revenue Ratio xenon-pharma.com (XENE)|Forward Price-to-Revenue Multiple VKTX|SUPN: Forward Price to Sales|Forward Price-to-Revenue Multiple CPRX (Catalyst Pharmaceuticals Inc)|Price to Expected Revenue Ratio DNLI|Forward P/S Multiple HRMY (Harmony Biosciences)|Forward Price to Sales BHVN|Amylyx Pharmaceuticals, Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Trevi Therapeutics Inc|Praxis Medicines (PRAX) - Price-to-Projected Revenue Ratio|Anavex Life Sciences Corp - Forward Price to Sales|CBLL (CeriBell, Inc.) - Forward P/S Multiple|Forward P/S Multiple Prothena Corporation|Price-to-Projected Revenue Ratio Alector, Inc. (ALEC)|ANNX: Future Price to Revenue|Forward P/S Multiple OMER (Omeros)|Neurogene Therapeutics (NGNE) - Market Cap to Future Revenue Ratio|ACIU: Forward Price-to-Revenue Multiple|VYGR - Forward P/S Multiple|NMRA (Neumora Therapeutics, Inc.) - Forward Price-to-Revenue Multiple|SCLX: Price to Expected Revenue Ratio|TVGN (Tevogen Bio Holdings, Inc.) - Forward P/S Multiple|Alpha Cognition Corp (ACOG) - Market Cap to Expected Sales Ratio|Forward P/S Multiple CGTX|Forward Price-to-Revenue Multiple inhibikase.com IKT|Price-to-Projected Revenue Ratio Cassava Sciences SAVA|Market Cap to Expected Sales Ratio Assertio Holdings (ASRT)|COYA - Price-to-Projected Revenue Ratio|VTGN (Vistagen Therapeutics) - Market Cap to Projected Revenue|ovidrx.com (OVID) - Price-to-Projected Revenue Ratio|acumenpharm.com - Forward Price to Sales|Price-to-Projected Revenue Ratio CervoMed|Alterity Therapeutics Ltd (ATHE) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Clene Inc. (CLNN)|pepgen.com - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Jupiter Neurosciences Inc JUNS|RLMD: Market Cap to Projected Revenue|Annovis Bio - Forward P/S Multiple|Market Cap to Future Revenue Ratio Grace Therapeutics, Inc.|AIFF (Firefly Neuroscience Inc) - Forward Price-to-Revenue Multiple|Klotho Neurosciences (KLTO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Reviva Pharmaceuticals|MTVA: Forward Price to Sales|Price-to-Projected Revenue Ratio NeurAxis (NRXS)|HSDT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Passage Bio PASG|NEUP: Market Cap to Projected Revenue|Minerva Neurosciences - Forward P/S Multiple|Market Cap to Future Revenue Ratio athira.com|ADXN (Addex Therapeutics Ltd) - Forward Price-to-Revenue Multiple|Alzamend Neuro (ALZN) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Cyclerion Therapeutics Inc.|PTIX: Forward Price to Sales|Price-to-Projected Revenue Ratio Pasithea Therapeutics (KTTA)|CRGT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Avenue Therapeutics, Inc. ATXI|Market Cap to Expected Sales Ratio Brainstorm Cell Therapeutics Inc. (BCLI)|Cara Therapeutics, Inc - Forward P/S Multiple|Market Cap to Future Revenue Ratio Chromocell|eliemtx.com (ELYM) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue ITCI|Price-to-Projected Revenue Ratio Longboard Pharmaceuticals, Inc.|Marinus Pharmaceuticals Inc (MRNS) - Market Cap to Expected Sales Ratio|Forward P/S Multiple NKGN|NRBO - Market Cap to Future Revenue Ratio|Sage Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales SNPX|TRVN: Forward Price-to-Revenue Multiple|Vigil Neuroscience - Price to Expected Revenue Ratio|WENA: Forward P/S Multiple|Cerevel Corp - Forward Price to Sales
